13F-HR filed by Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 30 holding rows worth $3,917,829,903.
- Accession
- 0001855655-26-000003
- Filer
- CIK 1855655
- Filed
- 2026-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 30 entries on the cover page, a total value of $3,917,829,903 stated on the cover page (in dollars after the unit check, H1), rows summing to $3,917,829,903 with VALUE read as dollars as filed, 13F file number 028-21950. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| NUVALENT INC COM | 670703107 | Stock | 5,269,433 | $530,052,265 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 6,644,403 | $529,226,699 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 5,724,016 | $373,205,843 | dollars as filed | |
| GENMAB A/S | 372303206 | Ordinary Shares, nominal value DKK 1 per share | 7,039,834 | $216,826,887 | dollars as filed | |
| TARSUS PHARMACEUTICALS INC | 87650L103 | COMMON STOCK | 2,562,154 | $209,789,170 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 1,417,473 | $191,153,321 | dollars as filed | |
| OLEMA PHARMACEUTICALS INC | 68062P106 | COM | 7,544,172 | $188,604,300 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 4,068,020 | $187,698,443 | dollars as filed | |
| SPDR SER TR | 78464A870 | S&P BIOTECH | 1,500,000 | $182,895,000 | dollars as filed | put |
| CIDARA THERAPEUTICS INC | 171757206 | COM NEW | 759,565 | $167,780,313 | dollars as filed | |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 6,541,210 | $162,320,126 | dollars as filed | |
| SCHOLAR ROCK HLDG CORP | 80706P103 | COM | 3,062,157 | $134,888,016 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 4,473,648 | $104,772,836 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 2,210,774 | $102,911,530 | dollars as filed | |
| APOGEE THERAPEUTICS INC COM | 03770N101 | Stock | 1,123,243 | $84,782,382 | dollars as filed | |
| EYEPOINT INC COM NEW | 30233G209 | Stock | 3,691,475 | $67,443,248 | dollars as filed | |
| ERASCA INC COM | 29479A108 | Stock | 14,159,095 | $52,671,833 | dollars as filed | |
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 684,277 | $52,340,348 | dollars as filed | |
| ORUKA THERAPEUTICS INC COM | 687604108 | Stock | 1,710,316 | $51,839,678 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 1,467,266 | $48,067,634 | dollars as filed | |
| LEXEO THERAPEUTICS INC | 52886X107 | COMMON STOCK | 4,763,198 | $47,298,556 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 1,443,102 | $44,909,334 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 2,935,284 | $35,634,348 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 810,286 | $32,735,554 | dollars as filed | |
| BRIDGEBIO ONCOLOGY THERAPEUT | 107924102 | COM NEW | 2,261,749 | $28,317,097 | dollars as filed | |
| VOR BIOPHARMA INC | 929033207 | COMMON STOCK | 1,750,000 | $22,890,000 | dollars as filed | |
| ASSEMBLY BIOSCIENCES INC | 045396207 | COMMON STOCK | 665,251 | $22,625,187 | dollars as filed | |
| ORIC PHARMACEUTICALS INC | 68622P109 | COM | 2,401,217 | $19,641,955 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 4,000,000 | $18,600,000 | dollars as filed | |
| KALARIS THERAPEUTICS INC | 482929106 | COM | 700,000 | $5,908,000 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001855655-26-000003 | this filing | 2026-02-17 | acceptance time not in the bulk data set |